Journal of Hospice and Palliative Care

  • 제19권3호
  • /
  • Pages.249-255
  • /
  • 2016
  • /
  • 2765-3072(pISSN)
  • /
  • 2765-3080(eISSN)
한국호스피스완화의료학회 (Korean Society for Hospice and Palliative Care)
권호 표지
DOI QR코드

DOI QR Code

Factors Associated with Ketamine Use in Pancreatic Cancer Patient in a Single Hospice Center

  • Kwon, Kyung Min (Department of Family Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Yong Joo (Department of Palliative Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Chang Jin (Department of Family Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Chul Min (Department of Palliative Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Jo Hi (Department of Palliative Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Min Hee (Department of Family Medicine, College of Medicine, The Catholic University of Korea)
  • 투고 : 2016.05.06
  • 심사 : 2016.08.12
  • 발행 : 2016.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 췌장암 환자의 90% 이상이 신경성 통증을 앓는 것으로 알려져 있으며 말기 췌장암 환자에서는 통증조절이 매우 중요한 목적 중 하나이다. 케타민은 NMDA 수용체 길항제로서 신경통에 효과가 있는 것으로 알려져 있으며 마약성 진통제의 요구를 감소시켜주는 효과에 대한 연구들이 앞서 진행된 바 있는 약물이다. 본 연구에서는 완화병동에 입원한 췌장암 환자들을 대상으로 케타민의 사용과 관련된 항목들을 알아보고 마약성 진통제를 줄여주는 효과를 나타내는지에 대해 진행한 연구이다. 방법: 2013년 1월부터 2014년 12월까지 서울성모병원완화의학과에 입원한 췌장암 환자 111명에 대한 의무기록을 통하여 케타민을 사용한 그룹(34명)과 사용하지 않은 그룹(77명)에 대해 케타민 사용과 관련된 요인 및 사용 후 모르핀을 포함한 마약성 진통제의 용량 변화를 분석하였다. 결과: 케타민을 사용한 군에서 사용하지 않은 군에 비하여 총 기본 마약성 진통제 사용량(P value 0.001), 하루에 사용한 마약성 진통제의 용량(P value<0.001), 평균 구제 약물의 용량(P value 0.001), 하루 평균 구제 약물 사용 횟수(P value 0.001), 하루 평균 구제 약물을 용량(P value<0.001)이 더 높게 나타났다. 케타민 사용 전후를 비교한 결과 마약성 진통제는 케타민 사용 전(76.1 (${\pm}64.5$))에 비하여 후(89.6 (${\pm}80.9$))에 유의하게 증가한 것으로 확인되었다. 결론: 후향적으로 의무기록 분석을 통해 이루어진 본 연구에서는 더 많은 용량의 마약성 진통제를 요한 환자들이 케타민을 사용한 경향이 확인되었다. 이와 더불어 케타민을 사용함으로 인해 마약성 진통제 요구량이 감소하는 경향은 확인할 수 없었다. 차후 더 많은 환자들과 다양한 종류의 암성 통증을 대상으로 한 완화의료적 목적의 케타민 사용에 대한 연구가 요할 것으로 생각되며 케타민의 사용에 관련된 가이드라인에 대한 논의가 요할 것으로 생각된다.

Purpose: Up to 90% of pancreatic cancer patients suffer from neuropathic pain. In a palliative care setting, pain control in pancreatic cancer patient is one of the major goals. Ketamine is a N-methyl-D-aspartate (NMDA) receptor antagonist, effective in neuropathic pain. Additionally, there have been studies about the opioid sparing effect of ketamine. This study was held in the palliative care unit among pancreatic cancer patients to determine the factors related to ketamine use and the opioid sparing effect. Methods: The medical records of pancreatic cancer patients admitted to St. Mary's hospital palliative care unit between January, 2013 and December, 2014 were reviewed. Patients were divided into 2 categories according to ketamine use. Also, opioid use before and after ketamine use was compared in the ketamine group. Results: Compared to the non-ketamine use group, patients in the ketamine group required a higher dose of opioid. The total opioid dose, daily opioid dose, number of daily rescue medications, and daily average rescue dose were statistically significantly higher in the ketamine group. The opioid requirement was increased after ketamine administration. Conclusion: In this retrospective study, ketamine was frequently considered in patients with severe pain, requiring higher amount of opioid. Studies about palliative use of ketamine in a larger number of patients with diverse types of cancer pain are required in the future.

키워드

참고문헌

  1. Erdek MA, King LM, Ellsworth SG. Pain management and palliative care in pancreatic cancer. Curr Probl Cancer 2013;37:266-72. https://doi.org/10.1016/j.currproblcancer.2013.10.003
  2. Barreto SG, Saccone GT. Pancreatic nociception--revisiting the physiology and pathophysiology. Pancreatology 2012;12:104-12. https://doi.org/10.1016/j.pan.2012.02.010
  3. Dobosz L, Kaczor M, Stefaniak TJ. Pain in pancreatic cancer: review of medical and surgical remedies. ANZ J Surg. In press 2016.
  4. Hirai I, Kimura W, Ozawa K, Kudo S, Suto K, Kuzu H, et al. Perineural invasion in pancreatic cancer. Pancreas 2002;24:15-25. https://doi.org/10.1097/00006676-200201000-00003
  5. Nagakawa T, Kayahara M, Ueno K, Ohta T, Konishi I, Ueda N, et al. A clinicopathologic study on neural invasion in cancer of the pancreatic head. Cancer 1992;69:930-5. https://doi.org/10.1002/1097-0142(19920215)69:4<930::AID-CNCR2820690416>3.0.CO;2-R
  6. Nakao A, Harada A, Nonami T, Kaneko T, Takagi H. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 1996;12:357-61. https://doi.org/10.1097/00006676-199605000-00006
  7. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin 2013;63:318-48. https://doi.org/10.3322/caac.21190
  8. Seicean A, Cainap C, Gulei I, Tantau M, Seicean R. Pain palliation by endoscopic ultrasound-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer. J Gastrointestin Liver Dis 2013;22:59-64.
  9. McQueen AL, Baroletti SA. Adjuvant ketamine analgesia for the management of cancer pain. Ann Pharmacother 2002;36:1614-9. https://doi.org/10.1345/aph.1A256
  10. Aroni F, Iacovidou N, Dontas I, Pourzitaki C, Xanthos T. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J Clin Pharmacol 2009;49:957-64. https://doi.org/10.1177/0091270009337941
  11. Kim SH, Kim SI, Ok SY, Park SY, Kim MG, Lee SJ, et al. Opioid sparing effect of low dose ketamine in patients with intravenous patient-controlled analgesia using fentanyl after lumbar spinal fusion surgery. Korean J Anesthesiol 2013;64:524-8. https://doi.org/10.4097/kjae.2013.64.6.524
  12. Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30:3611-7. https://doi.org/10.1200/JCO.2012.42.1081
  13. Kator S, Correll DJ, Ou JY, Levinson R, Noronha GN, Adams CD. Assessment of low-dose i.v. ketamine infusions for adjunctive analgesia. Am J Health Syst Pharm 2016;73(5 Suppl 1):S22-9. https://doi.org/10.2146/ajhp150367
  14. NCCN: Adult cancer pain NCCN guidelines [Internet]. Washington, PA: National Comprehansive Cancer Network; c2016. [cited 2016 Jun 08]. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  15. Campbell N, Boustani MA, Ayub A, Fox GC, Munger SL, Ott C, et al. Pharmacological management of delirium in hospitalized adults: a systematic evidence review. J Gen Intern Med 2009;24:848-53. https://doi.org/10.1007/s11606-009-0996-7
  16. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90:1528-33. https://doi.org/10.1097/00000542-199906000-00005
  17. Salas S, Frasca M, Planchet-Barraud B, Burucoa B, Pascal M, Lapiana JM, et al. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J Palliat Med 2012;15:287-93.
  18. Aroke EN, Dungan JR. Pharmacogenetics of Anesthesia: An Integrative Review. Nurs Res 2016;65:318-30. https://doi.org/10.1097/NNR.0000000000000164
  19. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999;82:111-25. https://doi.org/10.1016/S0304-3959(99)00044-5